Cart (0)
Login / Register
Search for:
Home
News
Articles
Fundraising
Diary
Company Archive
Home
Featured
ASX Market Wrap for Wednesday 17th September
Featured
The shifting face of Corporate Social Responsibility
Featured
Corporate Social Responsibility: a multidimensional challenge
Submit Your Email now, and get
Our Latest update
I have read and agree to the terms & conditions
Leave this field empty if you're human:
NEWS
Articles
Diary
events
Floats & Listings
Fundraising
News
AI is almost back
September 18, 2024
News
The Oxygen Project:
September 18, 2024
News
testing news
September 9, 2024
Fundraising
News
Tasmea edited IPO
April 9, 2024
Fundraising
News
D3 Energy Limited listing on ASX
April 9, 2024
Fundraising
News
Wrap and News
BlinkLab IPO
April 9, 2024
FUNDRAISING
N/A
this appear on home page and in FR table ?
N/A
TEST9999
test
Andrew and Shelley
IPO
Maintenance, engineering and sustaining capital service provider
Tasmea Limited ASX Listing
IPO
Oil and Gas Exploration
D3 Energy Limited
BlinkLab was incorporated on 17 August 2021 for the purpose of accelerating the development and commercialisation of intellectual property developed at Princeton University relating to smartphone-neurobehavioral testing (Licenced IP). BlinkLab has the exclusive worldwide licence to commercialise the Licenced IP and has developed a smartphone-based application with an e-platform that serves as a medical device to perform neurometric tests to aid in the diagnosis of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), schizophrenia and other neurodevelopmental conditions (BlinkLab Device). The tests include, but are not limited to, eyeblink conditioning (EBC), prepulse inhibition of acoustic startle (PPI) and habituation of eye blink response which serve as biomarkers for neurological and psychiatric disorders (BlinkLab Tests). The results from the BlinkLab Tests are recorded by smartphone and uploaded to BlinkLab’s confidential and secure online platform where the data is analysed using machine learning (ML). Upon admission, the primary focus of BlinkLab will be to complete the necessary regulatory clinical studies and obtain the necessary regulatory approvals (that being FDA approval in the US and CE Mark in Europe) to bring the BlinkLab Device to market initially as a diagnostic tool for ASD.
Blinklab Limited
IPO
1111
TestS
NSX
N/A
this is a t test
View more
ARTICLES
Articles
Does US Tax Overhaul Violate Global Trade Rules?
October 9, 2019
Articles
New Daring Street Style Trends Started by Gorgeous
October 9, 2019
Articles
NPO Show Will Return for Spring 2020 Premiere
October 9, 2019
Articles
Diary
events
Floats & Listings
Fundraising
News
AI is almost back
September 18, 2024
Articles
Article top new test
September 18, 2024
Articles
company new test
September 11, 2024
Articles
edit makes master ?The Oxygen Project – A global view from a tiny organism
May 9, 2024
Articles
ABB’s legal action against Superloops
September 18, 2024
AI Membership
AI Membership
$
99.00
AI
Join Now
Home Loans and Finance
$
0.00
Included in Membership
Join Now
Hotel Accomodation
$
0.00
Included in Membership
Join Now
Car Hire
$
0.00
Included in Membership
Join Now
Share trading
$
0.00
Included in Membership
Join Now
Login
Register
Remember me
Lost your password?
Login
Register